0
Iovance Biotherapeutics, Inc. Banner Image

Iovance Biotherapeutics, Inc. has reached its limit for free report views

Work for Iovance Biotherapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Iovance Biotherapeutics, Inc.

  • Ticker IOVA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Iovance Biotherapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in San Carlos, California
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused backMore into the patient. After infusion, TIL reach tumor tissue, where they attack tumor cells. The company has completed dosing in the pivotal study in patients with metastatic melanoma and is currently conducting a pivotal study in patients with advanced cervical cancer. In addition, the company’s TIL therapy is being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.
Iovance Biotherapeutics, Inc.

Most Recent Annual Report

Iovance Biotherapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Iovance Biotherapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports